Miguel Forte, CEO of Bone Therapeutics, walks through his journey leading the promising Belgian biotech company. He also shares with his view of the Belgian healthcare system and what makes the country a perfect environment for Bone Therapeutics as a biotech company focusing on innovative cell and gene therapy.
My goal is to shape the organization to deliver on clinical trials and engage with partners to bring in this innovation and potentially commercialize our assets in Europe and beyond
Belgian champion UCB’s global manufacturing head, Jacques Marbehant, talks candidly about managing a broad global manufacturing and supply chain through the COVID-19 pandemic, the talent challenges inherent in scaling up…
Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of…
Pierre Fabre Benelux General Manager Kristel de Bisschop discusses the challenges and opportunities inherent in taking charge of an important affiliate against the backdrop of a group-wide transformation push and…
The Top Five countries in Europe ranked by amount spent on pharma R&D. While some of the continent’s largest and most developed nations are represented, other smaller countries are punching…
While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as…
The new Belgian government has moved to streamline its response to the COVID-19 crisis with the appointment of Pedro Facon, director general for health at Belgium’s Federal Public Service Health…
See our Cookie Privacy Policy Here